Russian Heart Failure Journal 2009year Investigation of C677T metiltetragydrofolatreductase gene polymorphism in CHF patients.


To access this material please log in or register

Register Authorize
2009/

Investigation of C677T metiltetragydrofolatreductase gene polymorphism in CHF patients.

Pushkareva A. E., Valiev R. R., Husainova R. I., Husnutdinova N. N., Enikeeva G.R., Yusupova E. R., Husnutdinova E. K.

Keywords:

DOI:

Urgency. Reveal of the genetic factors iducted in heart remodelling process, let us look at the pathogenetic mechanisms of CHF development from enother side. One of the most investigateing genes–candidates on cardio–vascular pathology is gene – metiltetragydrofolatreductase (MTHFR), it’s allel variant exactly containing onenucleatid replacement. C677T. Aim. Investigate role of polymorphism C677T gene MTHFR in development of structure–functional remodelling of myocardium in CHF patients. Materials and methods. Material were collected from DNA of 280 CHF NYHA II–IV patients. Patients were divide in to 3 groups by LV myocardium remodelling type: with excentric hypertrophy and EF<40% (n=83), concentric moderate hypertrophy of LV (LVH) and preserved EF(n=79), and concentric severe hypertrophy of LV walls and preserved EF (n=118), and also DNA of healthy volounteers (n=190). In this trial statistyc, clinco–instrumental, molecular–biology ways of analyze were used. Study designed by case–control princip, includes estimation of the allel rate *T and henotype *T*T locus C677T in investigated and control groups, and also calculating of relative risk in depending of allel T quantity. Results. Allel quantum Assessment and henotype locus C^&&T result in statistically significant differencies between patients with severe LVH and healthy volounteers (p=0,012 and p=0,024) It was shown that henotype *t*T is genetic LVH marker. This fact can be an evidence of the homocistein system influence on the development of the hyperthrophyc process in LV. (OR=3,9;95% CI 1,38–11,25). Combination of henotypes *C*T and *T *T also increased LVH risk by 1,82 in comparison with gomozigots *C*C from control group(OR=1,82; CI 95% 1,14–2,89) . The association of C677T functional polymorphysm with excentric LVH were not found. Such way the possible role of MTHFR gene in severe concentric LVH was shown. By this, we can that further investigation are needed in this area, with inviting a wide specter of molecular–genetic and enviroment factors and possible corellation between them.
  1. Федеральная служба государственной статистики (www.gks.ru).
  2. Collins R. Heart Protection Study – Main results. Late breaking clinical trails. American Heart Association. Scientific Sessions 2001.
  3. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991; 121 (4 Pt 1):1244–1263.
  4. van der Put NM, Steegers-Theunissen RP, Frosst P et al. Mutated methylentetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995; 346 (8982):1070–1071.
  5. Gardemann A, Weidemann H, Philipp M et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J. 1999; 20 (8):584‑592.
  6. Morita H, Kurihara H, Tsubaki S et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol. 1998; 18 (9):1465–1469.
  7. Lee CN, Su YN, Cheng WF et al. Association of the C677T methylenetetrahydrofolate reductase mutation with congenital heart diseases. Acta Obstet Gynecol Scand. 2005; 84 (12):1134–1140.
  8. Giusti B, Porciani MC, Brunelli T et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome: possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J. 2003; 24 (22):2038–2045.
  9. Brattstrom L, Wicken D. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr. 2000; 72 (2):315‑323.
  10. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000; 72 (2):324‑332.
  11. Mathew, C. G. P. The isolation of high molecular weight eukaryotic DNA. In: J. M. Walker (ed.), Methods in Molecular Biology, Vol. 2, Chap. 5, pp. 31–34. New York: Humana Press, 1984.
  12. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10 (1):111‑113.
  13. Гланц С. Медико-биологическая статистика. – М.: «Практика», 1990. – 459с.
  14. Klerk M, Verhoef P, Clarke R, Blom H et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288 (16):2023–2031.
  15. Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994; 91 (14):6369–6373.
  16. Liu X, Luo F, Li J et al. Homocysteine induces connective tissue growth factor expression in vascular smooth muscle cells. J Thromb Haemost. 2008; 6 (1):184‑192.
  17. Malinow MR, Duell PB, Hess DL et al. Reduction of plasma homocyst (e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998; 338 (15):1009–1015.
  18. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274 (13):1049–1057.
  19. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst (e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268 (7):877‑881.
  20. Arnesen E, Refsum H, Bonaa KH et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995; 24 (4):704‑709.
  21. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106 (1):9–19.
  22. Evans RW, Shaten BJ, Hempel JD et al. Homocyst (e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997; 17 (10):1947–1953.
  23. Folsom AR, Nieto J, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1998; 98 (3):204‑210.
  24. Пузырев В. П., Макеева О. А., Голубенко М. В. Гены синтропий и сердечно-сосудистый континуум. Журнал Вестник ВОГиС. 2006; 10 (3):479‑491.

To access this material please log in or register

Register Authorize
Ru En